OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RFLNYSE$1.2763

Rafael Holdings, Inc.

PharmaceuticalsRules + LLM

Rafael Holdings exhibits a capital structure with a current ratio of 3.44, indicating strong liquidity, supported by $37.78 million in cash and equivalents as of January 31, 2026. The company's price-to-book ratio of 1.04 and price-to-tangible-book ratio of 1.04 suggest that the market values the company close to its book value, with no debt-to-equity leverage. Profitability metrics are negative, with a return on equity of -20.5% and return on assets of -16.34%, reflecting significant operational losses. The company reported a net loss of $16.23 million for the six months ended January 31, 2026, with operating income of -$16.80 million. These figures fall below the industry median for profitability, indicating underperformance relative to peers. The company's revenue is concentrated in a few segments, with the majority derived from product revenue and rental services. The six months ended January 31, 2026, saw total revenue of $451,000, with no significant geographic diversification disclosed in the financial statements. Growth trajectory is negative, with a year-over-year revenue decline. The six months ended January 31, 2026, reported $451,000 in revenue, compared to $205,000 in the same period in 2025. The outlook for the current fiscal year indicates continued challenges, with no significant revenue growth expected. Risk factors include medium dilution potential, with source documents mentioning dilution or offering risk. The company's liquidity risk is low, but the negative operating cash flow of -$14.33 million and free cash flow of -$14.33 million for the six months ended January 31, 2026, suggest ongoing cash flow challenges. Recent events include the filing of unaudited consolidated financial statements for Q2 2026, which show continued operational losses and cash flow outflows. The company also reported cash and equivalents of $37.78 million as of January 31, 2026, down from $45.54 million as of October 31, 2025.

30-day price · RFL+0.37 (+29.4%)
Low$1.22High$1.71Close$1.63As of8 Jun, 00:00 UTC
Profile
CompanyRafael Holdings, Inc.
ExchangeNYSE
TickerRFL
CIK0001713863
SICPharmaceutical Preparations
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals
IndustryPharmaceuticals
AI analysis

Business. Rafael Holdings, Inc. operates in the pharmaceuticals industry, primarily through its subsidiary Day Three, which provides technology to third-party manufacturers to enhance their product offerings.

Classification. Rafael Holdings is classified under the Pharmaceuticals industry within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.78.

Rafael Holdings exhibits a capital structure with a current ratio of 3.44, indicating strong liquidity, supported by $37.78 million in cash and equivalents as of January 31, 2026. The company's price-to-book ratio of 1.04 and price-to-tangible-book ratio of 1.04 suggest that the market values the company close to its book value, with no debt-to-equity leverage. Profitability metrics are negative, with a return on equity of -20.5% and return on assets of -16.34%, reflecting significant operational losses. The company reported a net loss of $16.23 million for the six months ended January 31, 2026, with operating income of -$16.80 million. These figures fall below the industry median for profitability, indicating underperformance relative to peers. The company's revenue is concentrated in a few segments, with the majority derived from product revenue and rental services. The six months ended January 31, 2026, saw total revenue of $451,000, with no significant geographic diversification disclosed in the financial statements. Growth trajectory is negative, with a year-over-year revenue decline. The six months ended January 31, 2026, reported $451,000 in revenue, compared to $205,000 in the same period in 2025. The outlook for the current fiscal year indicates continued challenges, with no significant revenue growth expected. Risk factors include medium dilution potential, with source documents mentioning dilution or offering risk. The company's liquidity risk is low, but the negative operating cash flow of -$14.33 million and free cash flow of -$14.33 million for the six months ended January 31, 2026, suggest ongoing cash flow challenges. Recent events include the filing of unaudited consolidated financial statements for Q2 2026, which show continued operational losses and cash flow outflows. The company also reported cash and equivalents of $37.78 million as of January 31, 2026, down from $45.54 million as of October 31, 2025.
Key takeaways
  • Rafael Holdings has a strong liquidity position with a current ratio of 3.44 and $37.78 million in cash and equivalents.
  • The company is unprofitable, with a return on equity of -20.5% and a net loss of $16.23 million for the six months ended January 31, 2026.
  • Revenue is concentrated in a few segments, with no significant geographic diversification.
  • The company faces medium dilution risk and has negative operating and free cash flows.
  • Recent financial filings indicate continued operational challenges and a decline in cash reserves.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodQ2 2026
CurrencyUSD
Revenue$451.0k
Gross profit
Operating income-$16.8M
Net income-$16.2M
R&D$12.0M
SG&A$5.1M
D&A
SBC$985.0k
Operating cash flow-$14.3M
CapEx$5.0k
Free cash flow-$14.3M
Total assets$99.3M
Total liabilities$16.1M
Total equity$79.2M
Cash & equivalents$37.8M
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$30.0k-$29.2M-$30.5M-$18.9M
FY2024$637.0k-$102.6M-$34.4M-$7.9M
FY2025$637.0k-$102.6M-$34.4M-$7.9M
FY2023$279.0k-$15.0M-$1.9M
FY2024$279.0k-$15.0M-$1.9M
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$114.1M$94.4M$52.8M
FY2024$96.8M$82.2M$2.7M
FY2025$96.8M$82.2M$2.7M
FY2023$98.8M$100.3M$21.5M
FY2024$98.8M$100.3M$21.5M
PeriodOCFCapExFCFSBC
FY2025-$18.9M$4.0k-$18.9M$2.1M
FY2024-$7.8M$143.0k-$7.9M$2.3M
FY2025-$7.8M$143.0k-$7.9M$2.3M
FY2023-$10.9M$2.2M
FY2024-$10.9M$2.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q2 2026$451.0k-$16.8M-$16.2M-$14.3M
Q1 2026$240.0k-$10.1M-$9.8M
Q2 2026
Q1 2026
PeriodGross %Op %Net %FCF %
Q2 2026
Q1 2026
Q2 2026
Q1 2026
PeriodAssetsEquityCashDebt
Q2 2026$99.3M$79.2M$37.8M
Q1 2026$105.4M$85.2M$45.5M
Q2 2026$89.2M
Q1 2026$114.1M$94.4M$52.8M
PeriodOCFCapExFCFSBC
Q2 2026-$14.3M$5.0k-$14.3M$985.0k
Q1 2026-$6.8M$598.0k
Q2 2026
Q1 2026
Valuation
Market price$1.27
Market cap$65.0M
Enterprise value$27.3M
P/E
Reported non-GAAP P/E
EV/Revenue60.5
EV/Op income
EV/OCF
P/B1.0
P/Tangible book1.0
Tangible book$62.4M
Net cash$37.8M
Current ratio3.4
Debt/Equity0.0
ROA-16.3%
ROE-20.5%
Cash conversion88.0%
CapEx/Revenue1.1%
SBC/Revenue2.2%
Asset intensity0.0
Dilution ratio
Risk assessment
Dilution riskMedium
Liquidity riskLow
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricRFLActivity
Op margin-3724.2%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-3599.3%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue2663.6%529.2% medp25 465.2% · p75 593.2%top quartile
CapEx / revenue1.1%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity0.0%25.0% medp25 3.8% · p75 63.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 05:19 UTC#1fac18fa
Market quoteclose USD 1.27 · shares 0.05B diluted
no public URL
2026-05-10 05:19 UTC#745c539d
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 04:57 UTCJob: ac8e811f